A key proteomics technology used to tackle the cancer proteome is multiplexing technology using isobaric tandem mass tags (TMT). In this ASMS 2016 breakfast workshop, Wilhelm Haas, Ph.D., Massachusetts General Hospital Cancer Center, discusses the use of proteomics as a technology to better understand cancer drug resistance. The throughput of multiplexed proteomics to quantitatively map 41 breast cancer cell lines is showcased, resulting in a total analysis time of 16.5 days, bringing the time to quantify a full proteome to only 4.5 hours. Dr. Haas also discusses proteome co-regulation and protein-protein association deregulation to reveal cell-line specific genes.
United States
